Area of research
Public Health, Environmental and Occupational Health · Epidemiology
Research interest
Research interests include Visceral leishmaniasis, Pharmacology, Chemistry, Biology, Leishmania donovani, and Leishmaniasis.
Synthesis and Anti-Chagas Activity Profile of a Redox-Active Lead 3-Benzylmenadione Revealed by High-Content Imaging
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc <sub>1</sub>
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility
Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal
Development of (6<i>R</i>)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5<i>H</i>-imidazo[2,1-<i>b</i>][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis
Discovery of benzimidazole‐based <i>Leishmania mexicana</i> cysteine protease <scp>CPB</scp>2.8Δ<scp>CTE</scp> inhibitors as potential therapeutics for leishmaniasis
The Challenges of Effective Leishmaniasis Treatment
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-<i>b</i>][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis
Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases
Ensemble‐based ADME–Tox profiling and virtual screening for the discovery of new inhibitors of the <i>Leishmania mexicana</i> cysteine protease CPB2.8ΔCTE
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond
Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent
Evaluating drug resistance in visceral leishmaniasis: the challenges
Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-<i>b</i>][1,3]oxazoles for Neglected Tropical Diseases: Structure–Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis
Potential of Lichen Secondary Metabolites against <i>Plasmodium</i> Liver Stage Parasites with FAS-II as the Potential Target
PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome
Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis
The Relevance of Susceptibility Tests, Breakpoints, and Markers